clinical trial · NCT06663319
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development, LLC·phase1·recruiting·n = 260
Colorectal NeoplasmsGastrointestinal NeoplasmsJNJ-89402638BevacizumabFOLFOXFOLFIRI
brief summary
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.
started
Oct 15, 2024
primary completion
Feb 25, 2028
completion
Jul 19, 2028
last updated
Jul 6, 2026
official title
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol